louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01702974: Immune Reconstitution in HIV Disease (IREHIV)
Official title: Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: HIV Infection
Keywords: HIV
cholecalciferol
sodium phenylbutyrate
antimicrobial peptides
immune response
inflammation
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: Addis Ababa University
name: Armauer Hansen Research Institute, Ethiopia
First posted: 2012-10-10
Enrollment: 279
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim with this study is to provide immunotherapy with vitamin D and phenylbutyrate to treatment-naive HIV infected patients to induce important antimicrobial defence mechanisms and decreased inflammation.


Eligibility criteria: Inclusion Criteria:

Adult patients \>18 years not subjected to HAART.

HIV-1 infected patients with CD4 T cells counts \>200 cells/ml.

Detectable plasma viral loads \>1000 copies/ml.

Exclusion Criteria:

Patients on HAART or other antimicrobial drugs (including bactrim).

Antimicrobial drug treatment in the past month.

Patients with medical contra-indication for biopsy such as bleeding tendencies.

Hypercalcaemia (serum calcium \> 3,0 mmol/L) identified at baseline.

Pregnant and breast feeding women.

Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.

Primary outcomes:
measure: HIV viral load
timeFrame: 0 (baseline) compared to 16 weeks.
Secondary outcomes:
measure: Clinical secondary endpoints
timeFrame: 0, 4, 8, 16, 24 weeks.
measure: Laboratory secondary endpoints
timeFrame: 0, 4, 8, 16, 24 weeks.
Other outcomes:
Locations:
city: Addis Ababa
country: Ethiopia
facility: Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine
state: Lideta sub city
Study officials:
affiliation: Karolinska Institutet
name: Susanna Brighenti, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Missailidis C, Sorensen N, Ashenafi S, Amogne W, Kassa E, Bekele A, Getachew M, Gebreselassie N, Aseffa A, Aderaye G, Andersson J, Brighenti S, Bergman P. Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1. Nutrients. 2019 Jul 21;11(7):1675. doi: 10.3390/nu11071675.
citation: Ashenafi S, Amogne W, Kassa E, Gebreselassie N, Bekele A, Aseffa G, Getachew M, Aseffa A, Worku A, Hammar U, Bergman P, Aderaye G, Andersson J, Brighenti S. Daily Nutritional Supplementation with Vitamin D(3) and Phenylbutyrate to Treatment-Naive HIV Patients Tested in a Randomized Placebo-Controlled Trial. Nutrients. 2019 Jan 10;11(1):133. doi: 10.3390/nu11010133.
Clinical trial NCT01099865: High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes
Official title: High-sensitivity C-reactive Protein and UKPDS Risk Score in Type 2 Diabetes: Nalysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atherosclerosis
Type 2 Diabetes
Lead sponsor: Korea University
Sponsor class: OTHER
First posted: 2010-04-08
Enrollment: 56
Sex: ALL
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: type 2 diabetes

Brief summary: The UKPDS risk score is recommended to assess global risk for future coronary heart disease (CHD) events in primary prevention. Recently, high-sensitivity C-reactive protein (hsCRP) has emerged as a strong independent risk factor for CHD. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising imaging technique for the evaluation of vascular inflammation that reflects vulnerable atherosclerotic plaque.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes

Exclusion Criteria:

* Myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization
* Resting blood pressure ≥160/100 mmHg
* Malignancy, or severe renal or hepatic disease
* Participants were free of any lipid-lowering therapies and postmenopausal hormone replacement therapy at least the 6 month period prior to enrollment
* History of inflammatory condition or those taking medications that might affect inflammatory status within 6 months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital Dept. of Endocrinology
Study officials:
References:
Clinical trial NCT06626165: Association Between Effectiveness of Mirikizumab and UC Patients with High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
Official title: Mirikizumab Therapy is Effective for Patients with Moderate to Severe Ulcerative Colitis Patients Whose Geboes Score Grade is ≥3.2) on Endoscopic Biopsy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Ulcerative Colitis
Keywords: ulcerative colitis
Lead sponsor: Showa Inan General Hospital
Sponsor class: OTHER
First posted: 2024-10-03
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to confirm that Mirikizumab therapy may provide clinical, endoscopic, and histopathologic improvements in patients with moderate to severe UC refractory to maintenance therapy when high neutrophilic infiltration in epithelium of the colonic mucosa (Geboes score Grade ≥3.2) on endoscopic biopsy is found.


Eligibility criteria: Inclusion Criteria:

* They were endoscopically active ulcerative colitis patients.

Exclusion Criteria:

* the presence of a long-term illness, colorectal cancer, or infectious colitis

Primary outcomes:
measure: Changes in clinical activities before and after mirikizumab or vedolizumab treatment.
timeFrame: 2 weeks
Secondary outcomes:
measure: Changes in endoscopic activities before and after mirikizumab or vedolizumab administration.
timeFrame: 2 months
measure: Changes in pathological activity
timeFrame: 2 months
Other outcomes:
Locations:
city: Komagane
country: Japan
facility: Showa Inan General Hospital
state: Nagano
Study officials:
References:
Clinical trial NCT05591365: Exercise Training in Coronary Artery Disease Patients After Stenting
Official title: Effects of Exercise Training on Cardiac Parameters in Coronary Artery Disease Patients After Stenting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stent Restenosis
Coronary Artery Disease
Keywords: Coronary artery diseases
Exercise training
Stenting
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-10-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the effect of exercise training on cardiac outcomes in coronary artery disease patients after Stenting. There is a need to develop strategies, not only to prevent restenosis but also to improve patients' functional status and perception of well-being. In particular, it is not well defined whether exercise training can reduce the restenosis rate and improve the outcome after PCI.

Detailed description: Based on an analysis of literature reviews, psychological symptoms (such as depression and anxiety), angina, vital exhaustion, and dyspnea have been observed to have the most significant influence on the quality of life in people with CAD. Almost half of the patients, after an initial encouraging improvement in functional capacity and quality of life (QOL) after the PCI, deal with recurrent chest pain that requires medical attention, reduces functional capacity, and creates a status of psychological distress.

Eligibility criteria: Inclusion Criteria:

* GCS = 15
* Disease chronicity: 1-3 years
* Elective / stenting procedure
* Single or Double vessel stunting
* EF: 35 above

Exclusion Criteria:

* Unwilling to participate in research
* Known cases of Uncontrolled DM or HTN
* Known cases of Cognitive/memory/neurological disorders
* Known cases of any Systemic disease

Primary outcomes:
measure: 6 min walk test: Distance (meters)
timeFrame: 12 weeks
measure: Mindfulness
timeFrame: 12 weeks
measure: Rate of perceived exertion (RPE)
timeFrame: 12 weeks
measure: Dyspnea
timeFrame: 12 weeks
measure: Mean arterial pressure
timeFrame: 3-5 days
measure: Heart Rate
timeFrame: 3-5 days
measure: Respiratory rate
timeFrame: 3-5 days
measure: Transcutaneous oxygen saturation [SpO2]
timeFrame: 3-5 days
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Armed forces institute of cardiology
state: Punjab
Study officials:
affiliation: Riphah International University
name: Mehwish Waseem, MSPT(CPPT)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00577265: An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication
Official title: An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: Asthma Control
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-12-20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients

Brief summary: An observational study to investigate how patients experience the ability to adjust their asthma maintenance medication according to instructions received from their physician. The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.


Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria: patients with prescription of budesonide/formoterol Turbuhaler 200/6 (adjustable maintenance dosing) and whom received instructions from their physician to adjust their asthma maintenance medication.

Primary outcomes:
measure: The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.
Secondary outcomes:
measure: The secondary goal is to investigate the efficacy of the treatment with budesonide/formoterol AMD on the patients asthma control measured with the ACQ.
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: Hannie de Munnik
role: STUDY_DIRECTOR
affiliation: AstraZeneca
name: Monique Scholtes
role: STUDY_CHAIR
References:
Clinical trial NCT05580965: Blood Sample Collection in Geriatric Patients
Official title: The Effect of Duration of Pressure Applied After Blood Sample Collection on the Development of Ecchymosis in Geriatric Patients Using Oral and Subcutaneous Anticoagulants: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Venipuncture Site Bruise
Lead sponsor: Saglik Bilimleri Universitesi
Sponsor class: OTHER
First posted: 2022-10-14
Enrollment: 164
Sex: ALL
Minimum age (years): 65
Maximum age (years): 93
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: This study aimed to evaluate the effect of different durations of a specific pressure applied after blood collection on the development of ecchymosis in geriatric patients using oral and subcutaneous anticoagulants.

Detailed description: The research sample consisted of patients hospitalized in the Geriatrics Clinic of a city hospital. This study aimed to evaluate the effect of different durations of a specific pressure applied after blood collection on the development of ecchymosis in geriatric patients using oral and subcutaneous anticoagulants. In this study, whether ecchymosis developed at the 24th, 48th and 72nd hours after the blood collection procedure was evaluated.

Eligibility criteria: Inclusion Criteria:

* patients aged 65 years and over
* who voluntarily agreed to participate in the study
* who used oral (Rivaroxaban 10-15-20 mg, Dabigatran, 75-110-150 mg, Apixaban 2.5-5 mg) and subcutaneous (Enoxaparin sodium 6000-4000 anti-Xa IU/0.6-0.4 ml) anticoagulants
* who were literate in Turkish
* who were scheduled for blood collection
* who would undergo blood collection from the antecubital site with vacutainer

Exclusion Criteria:

* patients with communication problems
* patients with hematoma, ecchymosis, and scarring in the antecubital site
* patients who would be discharged before 72 hours
* patients with coagulation disorders

Primary outcomes:
measure: number of participants with ecchymosis developed.
timeFrame: at the 24 th hours
measure: number of participants with ecchymosis developed.
timeFrame: at the 48 th hours
measure: number of participants with ecchymosis developed.
timeFrame: at the 72 nd hours
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Tulay Basak
Study officials:
affiliation: Saglik Bilimleri Universitesi
name: Tülay Başak
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06583265: Impact of Endometrial Compaction on Clinical Pregnancy Rate in Frozen Embryo Transfers
Official title: Impact of Endometrial Compaction on Clinical Pregnancy Rate in Frozen Embryo Transfers
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: IVF
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-09-04
Enrollment: 80
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infertility patients planning for FET

Brief summary: To find out if the percentage of endometrial compaction is correlated to clinical pregnancy rate in down regulated frozen embryo transfer cycle. Endometrial compaction is the change in endometrial thickness between the end of the estrogen only phase and the day of embryo transfer. In concept, the compaction of the endometrium after progesterone initiation indicates that the endometrium is responsive to progesterone and could therefore be used as a proxy for endometrial receptivity predictability of FET cycle outcome


Eligibility criteria: Inclusion Criteria:

* Women undergoing down regulated cycles frozen embryo transfer.
* Women at age group 20-35 years old.
* Day 5 embryos will be transferred.

Exclusion Criteria:

* Chromosomal abnormality in either partner (As this could lead to cycle cancellation).
* Uterine malformation or any intrauterine condition affecting the pregnancy outcomes of FET, such as endometrial polyps, uterine cavity adhesion, history of endometrial tuberculosis, hydrosalpinx with a reflux into uterine cavity (As the might not be candidates for IVF cycle till correction).
* Recurrent implantation failure, defined as 2 or more previous failed trials (Other confounding factors might of present which could affect the results).
* Cycles of patients with persistent endometrial thickness \<7mm during treatment protocol (Due to cycled cancelation).

Primary outcomes:
measure: clinical pregnancy rate
timeFrame: 3-4 wks after ET
Secondary outcomes:
measure: Percentage of change of endometrial thickness between the end of estrogen administration only phase and the day of embryo transfer.
timeFrame: 3-4 wks after ET
measure: Chemical pregnancy rates, detected by positive hCG test in the absence of pregnancy findings on TVUS
timeFrame: 3-4 wks after ET
measure: Number of estrogen administration days
timeFrame: 10 days before ET
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
References:
Clinical trial NCT02744365: Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications
Official title: Biobank of Data and of Human Biological Samples on Prematurity, Preeclampsia and Other Pregnancy Complications
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Preeclampsia
Preterm Birth
Pregnancy Complications
Fetal Anomalies
Lead sponsor: CHU de Quebec-Universite Laval
Sponsor class: OTHER
First posted: 2016-04-20
Enrollment: 7845
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: According to each study:

1. Prediction study: Nulliparous women between 11 and 13 6/7 weeks of gestation
2. PEARL study: Nulliparous women between 11 and 13 6/7 weeks of gestation or diagnosed with preeclampsia between 20 and 42 weeks of gestation
3. GAP Study: women with twin pregnancy between 11 and 13 6/7 weeks of gestation
4. Prediction-2 study: Nulliparous women with singleton pregnancy without fetal anomaly/demise between 14 and 15 6/7 weeks of gestation

Brief summary: The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.

Detailed description: This Biobank is comprised of: 1) medical, social, obstetrical and ultrasonographic data, 2) human biological samples (maternal plasma, serum and buffy coat, maternal urine, cord blood) and 3) the results derived from these (biochemical or ultrasonographic markers, genetics, risk calculations ...)

Eligibility criteria: Inclusion Criteria:

* (specific to each study)

Exclusion Criteria:

* pregnant women \<18 years old at recruitment
* negative fetal heart at recruitment
* women not able to provide an informed consent to the study

Primary outcomes:
measure: early onset preeclampsia
timeFrame: diagnosed between 20 and 34 weeks of gestation
Secondary outcomes:
measure: Severe preeclampsia
timeFrame: between 20 and 42 weeks of gestation
measure: Fetal growth restriction
timeFrame: between 20 and 42 weeks of gestation
measure: spontaneous preterm birth
timeFrame: between 20 and 36 6/7 weeks of gestation
measure: Fetal aneuploidies
timeFrame: diagnosed during or after pregnancy
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: CHU de Quebec
Study officials:
affiliation: CHU de Quebec
name: Emmanuel Bujold, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00794365: Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
Official title: Post-Marketing Surveillance Study To Observe The Safety And Effectiveness Of Varenicline (Champix) Tablets In Smoking Cessation Among Filipino Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking Cessation
Keywords: Smoking; smoking cessation; Philippines; Varenicline
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-11-20
Enrollment: 330
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This post-marketing surveillance study will be conducted nationwide and will enroll approximately 3,000 study patients. Subject enrollment of less than 3,000 will be acceptable in case of less than expected use of Varenicline (Champix™) by physicians.

Brief summary: The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks among Filipino smokers.

The secondary objective is to further evaluate the effectiveness of Varenicline (Champix™) as an aid in smoking cessation based on the 7-day point prevalence of smoking cessation

Detailed description: The study will enroll smoking patients.

Eligibility criteria: Inclusion Criteria:

* Smoking adults aged ≥ 18 years intending to quit tobacco use who are prescribed Varenicline (Champix™) by their Physicians and those who are prescribed with Varenicline (Champix™) for the first time.

Exclusion Criteria:

* Subjects in whom varenicline (Champix™) may be taken in a manner that is not according to the approved local product document.
* Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception
* Subjects with known hypersensitivity to varenicline.

Primary outcomes:
measure: Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 4
timeFrame: Week 4
measure: Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 8
timeFrame: Week 8
measure: Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 12
timeFrame: Week 12
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Park PW, Casiano EM, Escoto L, Claveria AM. Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers. Curr Med Res Opin. 2011 Oct;27(10):1869-75. doi: 10.1185/03007995.2011.607436. Epub 2011 Aug 12.
Clinical trial NCT01354665: Depression and Fatigue in MS Patients Treated With Betaferon.
Official title: The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Keywords: Multiple sclerosis
Interferon beta-1b
Fatigue
Depression
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2011-05-17
Enrollment: 567
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with relapsing form of multiple sclerosis treated with Betaferon under routine practice setting.

Brief summary: This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.

The study is conducted in routine practice setting hence no interference with standard care takes place.

Pharmacologic treatments of MS-fatigue and depression will also be recorded.


Eligibility criteria: Inclusion Criteria:

* Relapsing-remitting multiple sclerosis
* Age 18+
* Patients initiating Betaferon treatment

Exclusion Criteria:

* Patients previously treated with any immunomodulatory drug

Primary outcomes:
measure: Changes of fatigue score over time
timeFrame: short-term, mid-term and long-term changes will be assessed: 3 months vs. baseline, 6 months vs. baseline and 12 months vs. baseline
Secondary outcomes:
measure: Changes of depression score over time
timeFrame: short-term, mid-term and long-term changes will be assessed: 3 months vs. baseline, 6 months vs. baseline and 12 months vs. baseline
measure: Treatment adherence
timeFrame: 12 months
measure: Clinical course of the disease
timeFrame: 12 months
measure: Overall treatment tolerability as measured by rate of adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Many Locations
country: Poland
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: